Across TCGA pan-cancer cohorts, CCDC59 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CCDC59 data layer compared with 23 for mass-spec protein and 6 for mass-spec protein.
The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher CCDC59 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CCDC59 expression acts as an unfavorable survival marker.
LUSC, LIHC, and UCEC are the cancer types where CCDC59 Mutation most reproducibly stratifies survival.